Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ADPT.NASDAQ

Adaptive Biotechnologies Corp (ADPT NASDAQ) stock market data APIs

$4.45 -0.06(-1.3%) as of July 26, 2024
Price chart is built with Anychart

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corp Financial Data Overview

4.51
4.45
-
4.75
4.35
2.28-8.51
657 M
147 M
175 M
-0.33
1.347
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ADPT',
Type: 'Common Stock',
Name: 'Adaptive Biotechnologies Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG001J2PFF5',
ISIN: NULL,
CUSIP: NULL,
CIK: '1478320',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2019-06-27',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Adaptive Biotechnologies Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 175 M
  • EBITDA -171 152 992
  • Earnings Per Share -1.49
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Adaptive Biotechnologies Corp Earnings via APIs

  • Latest Release 2024-05-07
  • EPS/Forecast -0.34

Get Adaptive Biotechnologies Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Adaptive Biotechnologies Corp latest news via APIs

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Adaptive Biotechnologies SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Adaptive Biotechnologies More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 3...
Do you have any questions?
support@eodhistoricaldata.com